Program
Itraconazole
Also written as “itraconazole”, “Itraconazole (200 mg)” and “Itraconazole Powder”.
Its studies are mostly in HIV Infections · Hematologic Neoplasms · Asthma · Neutropenia · Onychomycosis, led by 9 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 100 open or running | phase 4since Feb 13, 2009 | Nov 2, 1999 | none ahead |
| AstraZeneca | 60 open or running | phase 1since Jul 12, 2013 | Jul 12, 2013 | none ahead |
| GlaxoSmithKline | 30 open or running | phase 3since Jul 25, 2006 | Jul 25, 2006 | none ahead |
| Pfizer | 30 open or running | phase 1since Mar 27, 2014 | Mar 27, 2014 | none ahead |
| Pulmatrix | 30 open or running | phase 2since May 14, 2019 | Feb 5, 2018 | none ahead |
| GRIN Therapeutics | 21 open or running | phase 1since Apr 11, 2025 | Apr 11, 2025 | none ahead |
| Lomond Therapeutics | 20 open or running | phase 1since May 1, 2024 | May 1, 2024 | none ahead |
| mayne-pharma-international-pty-ltd | 20 open or running | phase 4since Dec 2, 2015 | Dec 2, 2015 | none ahead |
| Boryung Pharmaceutical | 10 open or running | phase 1since Jul 7, 2015 | Jul 7, 2015 | none ahead |
Also a collaborator on its studies: parexel, avance-clinical-pty-ltd, arvinas-estrogen-receptor-inc, cambridge-cognition-ltd and covance.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 18 studies since Nov 2, 1999.
- Sep 6, 2016Phase 4 study in Hematologic NeoplasmsJohnson & Johnson · NCT02895529 · 61 enrolled · China
- Feb 5, 2018Pulmatrix's first study: phase 1 study in AsthmaNew to PulmatrixPulmatrix · NCT03479411 · 58 enrolled · United Kingdom
- Feb 14, 2019Phase 1 study in Heart FailureAstraZeneca · NCT03843060 · 14 enrolled · United States
- Apr 18, 2019Phase 4 study in MycosesJohnson & Johnson · NCT03923010 · 40 enrolled · India
- May 14, 2019Phase 2 study in Aspergillosis, Allergic BronchopulmonaryPulmatrix · NCT03960606 · 7 enrolled · United States, Australia, India and more
- Dec 15, 2020Phase 1 study in Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer)AstraZeneca · NCT04712396 · 11 enrolled · Germany
- Jun 8, 2021Phase 1 study in Advanced Solid TumoursAstraZeneca · NCT04959266 · 5 enrolled · United States, Spain
- Sep 8, 2022Phase 1 study in HealthyPfizer · NCT05538312 · 12 enrolled · Belgium
- Dec 1, 2022Phase 2 study in AsthmaPulmatrix · NCT05667662 · 8 enrolled · United States, Australia, France and more
- Apr 5, 2024Phase 1 study in Healthy ParticipantsAstraZeneca · NCT06357520 · 14 enrolled · United States
- May 1, 2024Lomond Therapeutics's first study: phase 1 study in AMLNew to Lomond TherapeuticsLomond Therapeutics · NCT06399315 · 112 enrolled · Australia
- Jan 16, 2025Phase 1 study in Leukemia, Lymphocytic, Chronic, B-CellLomond Therapeutics · NCT06787131 · 104 enrolled · Australia
- Apr 11, 2025GRIN Therapeutics's first study: phase 1 study in Tuberous SclerosisNew to GRIN TherapeuticsGRIN Therapeutics · NCT06965881 · 30 enrolled · Australia
- Oct 8, 2026Phase 1 study in Healthy Adult ParticipantsGRIN Therapeutics · NCT07884734 · 36 enrolled · United States
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Cytochrome P450 51 inhibitor”ChEMBL 37, by rule
Studies
All 32 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07884734Healthy Adult Participants · United States | 1 | Active, not recruiting | GRIN Therapeutics | Oct 31, 2026 | 36 |
| NCT06965881Tuberous Sclerosis · Australia | 1 | Terminated | GRIN Therapeutics | Jul 8, 2025 | 30 |
| NCT06787131Leukemia, Lymphocytic, Chronic, B-Cell · Australia | 1 | Completed | Lomond Therapeutics | Jul 4, 2025 | 104 |
| NCT06399315AML · Australia | 1 | Completed | Lomond Therapeutics | Jun 30, 2025 | 112 |
| NCT06357520Healthy Participants · United States | 1 | Completed | AstraZeneca | Jun 17, 2024 | 14 |
| NCT05667662Asthma · United States, Australia, France and more | 2 | Terminated | Pulmatrix | Feb 27, 2024 | 8 |
| NCT05538312Healthy · Belgium | 1 | Completed | Pfizer | Apr 24, 2023 | 12 |
| NCT04959266Advanced Solid Tumours · United States, Spain | 1 | Terminated | AstraZeneca | Jun 1, 2022 | 5 |
| NCT04712396Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer) · Germany | 1 | Completed | AstraZeneca | Mar 25, 2021 | 11 |
| NCT03960606Aspergillosis, Allergic Bronchopulmonary · United States, Australia, India and more | 2 | Terminated | Pulmatrix | Jul 14, 2020 | 7 |
| NCT03923010Mycoses · India | 4 | Terminated | Johnson & Johnson | Mar 25, 2020 | 40 |
| NCT03843060Heart Failure · United States | 1 | Completed | AstraZeneca | Apr 1, 2019 | 14 |
| NCT03479411Asthma · United Kingdom | 1 | Completed | Pulmatrix | Jun 28, 2018 | 58 |
| NCT02895529Hematologic Neoplasms · China | 4 | Terminated | Johnson & Johnson | May 2, 2018 | 61 |
| NCT02755857Neutropenia · Australia | 2 | Completed | mayne-pharma-international-pty-ltd | Dec 2016 | 20 |
| NCT02621905Neutropenia · Australia | 4 | Completed | mayne-pharma-international-pty-ltd | Nov 2016 | 40 |
| NCT02493738Dermatomycoses · Korea, Republic of | 1 | Completed | Boryung Pharmaceutical | Oct 2015 | 24 |
| NCT02131298Healthy · United States | 1 | Completed | Pfizer | Jun 2014 | 12 |
| NCT02130661Alzheimer Disease | 1 | Withdrawn | GlaxoSmithKline | Jan 2018 | 0 |
| NCT02100553Obesity · United States | 1 | Completed | Pfizer | Jun 2014 | 24 |
| NCT02093728Solid Tumours · United States | 1 | Completed | AstraZeneca | Jun 2014 | 26 |
| NCT01900028Neoplasms · Belgium, Denmark, Netherlands and more | 1 | Completed | AstraZeneca | Apr 2014 | 85 |
| NCT01823289Lung Diseases, Fungal | 4 | Completed | Johnson & Johnson | Dec 2008 | 71 |
| NCT00871728Onychomycosis | 4 | Completed | Johnson & Johnson | May 2009 | 132 |
| NCT00695071Healthy · United States | 1 | Completed | GlaxoSmithKline | Jul 2008 | 16 |
| NCT00356915Onychomycosis · United States, Canada, Dominican Republic and more | 3 | Completed | GlaxoSmithKline | Oct 2008 | 1,381 |
| NCT00002438HIV Infections · United States | – | Completed | Johnson & Johnson | ||
| NCT00002370HIV Infections · United States | – | Completed | Johnson & Johnson | 36 | |
| NCT00002341Candidiasis, Oral · United States | – | Completed | Johnson & Johnson | ||
| NCT00002159HIV Infections · United States | 3 | Completed | Johnson & Johnson | 60 | |
| NCT00002133Candidiasis, Oral · United States | – | Completed | Johnson & Johnson | ||
| NCT00002132Candidiasis · United States | – | Completed | Johnson & Johnson |
How it is read
Names in the registry
- “Itraconazole”, 40 entries
- “itraconazole”, 5 entries
- “Itraconazole (200 mg)”, 4 entries
- “Itraconazole Powder”, 2 entries
- “Lozanoc”, 2 entries
Codes read as this program: PUR1900.
Conditions, from the studies’ own filings
- HIV Infections, 3 studies
- Hematologic Neoplasms, 2 studies
- Asthma, 2 studies
- Neutropenia, 2 studies
- Onychomycosis, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.